Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Biotech Stocks to Watch Leading Up to ASCO

By

Some key companies to watch as the American Society of Clinical Oncology conference nears.

PrintPRINT
The American Society of Clinical Oncology conference is rapidly approaching and that means it's time to get further entrenched in some of the biotech stocks that will likely benefit from the conference's exposure to the medical and investment ilk alike.

This year, from June 4 to June 8, Chicago will host ASCO, where more than 250 companies will present data on upcoming cancer drugs with hopes of finding a better treatment and maybe even a cure. While some companies have already released details of what their presentations will entail, the full abstracts will be available on the ASCO website on May 20. Biotech and pharma stocks tend to see a good increase prior to the conference and could jump on any significant results that are released at the conference -- so now is the time to put your money down. Here are a few stocks to consider adding to your portfolio:

Delcath Systems (DCTH):
The medical device company will be presenting the full phase III data from trials that tested its Percutaneous Hepatic Perfusion system, which delivers chemotherapy directly to the liver instead of exposing a cancer patient's entire body to the toxic chemicals.

Shares of the company jumped 25% after it announced preliminary results of the study findings in April. Analysts anticipate an on-label market of the technology to reach about $550 million, while off-label uses could be as lucrative as $4.5 billion. If approved, Delcath hopes to have the system to market by the second half of 2011.

Ziopharm Oncology (ZIOP):
The biopharma will be presenting data from its phase II study of palifosfamide in combination with doxorubicin as compared to patients just taking doxorubicin for the treatment of soft-tissue sarcoma, or cancer of the tissues that surround the organs of the body like bone or muscle. Results from phase I trials showed the drug to be well-tolerated with no dose-limiting toxicities. Ziopharm is planning another phase III study of palifosfamide in soft-tissue sarcoma for later this year.

The stock has gone from trading at under a dollar at this time last year to trading at more than $6 currently. Expect to see the price go higher as the developmental stage company moves things further along in its pipeline.

CellDex Therapeutics (CLDX):
The biotech will be presenting data from its phase II trial of CDX-110 (PF-04948568), which it's partnered on with Pfizer (PFE), for the treatment of glioblastoma, a really aggressive form of brain cancer.

Expect to see this stock take a major leap if the data are positive. The drug helps to boost a patient's immune system to fight the cancer, making it a vaccine. This stock has gained plenty of interest since Dendreon (DNDN) received approval for its prostate cancer vaccine Provenge -- the first cancer vaccine to get FDA approval. CellDex is already up 91% year-to-date.

(Check out Minyanville Professor David Miller's article Finding the Next Dendreon)

Pharmacyclics (PCYC):
The biopharma is expected to present data on its Btk inhibitor PCI-32765 monotherapy for the treatment of patients who have relapsed non-Hodgkin's lymphoma. Earlier studies showed antitumor activity. The price of the stock has more than doubled since the beginning of the year.

Celgene (CELG):
The biotech will be presenting further data on its best-selling product Revlimid, which is already approved as a second line of defense in combination with dexamethason in patients with multiple myeloma. The data will be from two studies showing the effects of Revlimid following single autologous stem cell transplant for multiple myeloma, a blood cancer. Celgene is hoping to show Revlimid is useful as a maintenance therapy. It also plans to file for approval of Revlimid as a first-line treatment before the end of the year. Analysts expect this drug to grow into a $5 billion-a-year drug by 2015.

Buzz & Banter: 30 professional traders sharing trading ideas in real-time. FREE 14 day trial.
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

PrintPRINT
 
Featured Videos

WHAT'S POPULAR IN THE VILLE